Dalpiciclib in HR+/HER2- ABC
To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.
Advanced Breast Cancer
DRUG: dalpiciclib
Progression-Free Survival, The time from the date of starting dalpiciclib to the date of disease progression as per RECIST version 1.1 or death from any cause, whichever occurs first., From the date of starting dalpiciclib to the date of first documentation of progression or death (up to approximately 1 years)
Adverse events, Adverse events during dalpiciclib treatment will be assessed according to the NCI CTCAE v5.0., From the date of starting dalpiciclib to the end of the treatment (up to approximately 1 year)
To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.